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Abstract
Patients classified as idiopathic pulmonary arterial hypertension (defined as Group 1 on European Respiratory Society (ERS)/
European Cardiac Society (ESC) criteria) may have evidence of minor co-existing lung disease on thoracic computed tomography.
We hypothesised that these idiopathic pulmonary arterial hypertension patients (IPAH lung disease) are a separate subgroup of
idiopathic pulmonary arterial hypertension with different phenotype and outcome compared with idiopathic pulmonary arterial
hypertension patients without co-existing lung disease (IPAH no lung disease). Patients with ‘IPAH lung disease’ have been eligible for all
clinical trials of Group 1 patients because they have normal clinical examination and normal spirometry but we wondered whether
they responded to treatment and had similar survival to patients with ‘IPAH no lung disease’. We described the outcome of the cohort
of patients with ‘IPAH no lung disease’ in a previous paper. Here, we have compared incident ‘IPAH lung disease’ patients with ‘IPAH no lung
disease’ patients diagnosed concurrently in all eight Pulmonary Hypertension centres in the UK and Ireland between 2001–2009.
Compared with ‘IPAH no lung disease’ (n¼ 355), ‘IPAH lung disease’ patients (n¼ 137) were older, less obese, predominantly male, more
likely to be current/ex-smokers and had lower six-minute walk distance, lower % predicted diffusion capacity for carbon monoxide,
lower mean pulmonary arterial pressure and lower pulmonary vascular resistance index. After three months of pulmonary
hypertension-targeted treatment, six-minute walk distance improved equally in ‘IPAH lung disease’ and ‘IPAH no lung disease’. However,
survival of ‘IPAH lung disease’ was lower than ‘IPAH no lung disease’ (one year survival: 72% compared with 93%). This survival was
significantly worse in ‘IPAH lung disease’ even after adjusting for age, gender, smoking history, comorbidities and haemodynamics. ‘IPAH
lung disease’ patients had similar short-term improvement in six-minute walk distance with anti-pulmonary arterial hypertension
therapy but worse survival compared with ‘IPAH no lung disease’ patients. This suggests that ‘IPAH lung disease’ are a separate phenotype
and should not be lumped with ‘IPAH no lung disease’ in clinical trials of Group 1 pulmonary arterial hypertension.
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Introduction
The demographics of idiopathic pulmonary arterial hyper-
tension (IPAH) has changed over the past decade compared
with IPAH patients from the era of the NIH registry.1,2
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We have previously shown that younger subgroup of IPAH
have different phenotype and survival compared with the
older subgroup of IPAH.1 Patients with evidence of lung
disease on thoracic computed tomography (CT) were
excluded from that study. Recently, Trip et al. identified a
subgroup of IPAH characterised by severely reduced diffu-
sion capacity and associated the poor survival of those
patients with old age, male gender and co-existing coronary
disease.3 We hypothesised that IPAH patients with co-exist-
ing lung disease on thoracic CT (referred to as ‘IPAH lung
disease’ in this study) are a separate subgroup of IPAH. The
objective of this study was to describe the phenotype of
‘IPAH lung disease’ and compare them with IPAH patients
without co-existing lung disease (referred to as ‘IPAH no
lung disease’ in this study) diagnosed and treated concurrently
over the study period in all eight pulmonary hypertension
(PH) centre in the UK and Ireland. We also aimed to deter-
mine whether the presence of co-existing lung disease on
thoracic CT without clinical signs of lung disease or spiro-
metric abnormalities has any impact on the response to PH-
targeted treatment and survival of ‘IPAH lung disease’.
Methods
We identified all consecutive, treatment naı¨ve, incident cases
of IPAH diagnosed in all eight PH centres in the UK and
Ireland between the 1 January 2001 and 31 December 2009.
The diagnosis of IPAH was based on standard criteria used
by all UK expert PH centres. All patients underwent
multimodality assessment for their PH. This includes six-
minute walk test, pulmonary function test, thoracic CT
and right heart catheterisation (RHC). Patients were
excluded if they had a family history or associated causes
for their pulmonary arterial hypertension (PAH). We
applied similar pulmonary function test exclusion criteria
(defined in this study as forced expiratory volume in one
second (FEV1), forced vital capacity (FVC) or total lung
capacity <60% predicted) employed in randomised con-
trolled trials of PAH to exclude Group 3 PH patients.
Any patients who may also have had Group 2, Group 4
or Group 5 PH were also excluded. Patients were then
divided into ‘IPAH no lung disease’ or ‘IPAH lung disease’ based
on the presence or absence of minor co-existing lung disease
on thoracic CT. Only emphysema and/or pulmonary fibrosis
were included as co-existing lung disease in this study. These
patients had no symptoms or signs of lung disease with the
exception of breathlessness and had normal spirometry.
Fig. 1 shows the flow chart of patients’ selection as
‘IPAH no lung disease’ or ‘IPAH lung disease’.
The date of diagnostic right heart catheter (RHC) was
taken as the date of diagnosis. Four patients were too unwell
to have RHC at the time of diagnosis and were started on
empirical PH treatment. All four patients had follow-up
RHC confirming pre-capillary PH.
We compared the baseline characteristics, treatments and
outcomes of ‘IPAH lung disease’ against ‘IPAH no lung disease’
diagnosed and treated concurrently over the study period.
Due to the nature of the study, ethical approval was deemed
Fig. 1. Flow diagram showing patient selection for ‘IPAH lung disease’ and ‘IPAH no lung disease’.
CPFE: combined pulmonary fibrosis and emphysema; CT: computed tomography; %FEV1: % predicted forced expiratory volume in second; %
FVC: % predicted forced vital capacity; IPAH: idiopathic pulmonary arterial hypertension; % TLC: % predicted total lung capacity; PAH: pulmonary
arterial hypertension; PH: pulmonary hypertension.
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unnecessary by the West of Scotland Research Ethics
Committee.
Statistical analysis
Analyses were performed using SPSS version 22 (SPSS,
Chicago, IL). For quantitative variables, mean  standard
deviation was used to describe parametric data, whereas
median and interquartile range were used for non-parametric
data. Comparisons between two independent groups were
performed using Student’s t test or Mann–Whitney U test.
Categorical variables were described by frequencies and per-
centages and comparisons between groups performed using
2 or Fisher’s exact tests. Survival endpoint was taken as
either date of death/transplant or censoring. Patients were
censored if they were lost to follow up (date of last visit to
PH centre was used as censor date) or if they were alive on
the last day of the study (31 December 2009). Mortality was
confirmed using PH centre records, general practitioner and
NHS strategic tracing services. All-cause mortality was used
in survival analyses. Survival from time of diagnosis was
estimated using the Kaplan–Meier method. Multivariate
Cox regression was used to compare the survival of ‘IPAH
lung disease’ against ‘IPAH no lung disease’ after adjusting for
potential confounders identified from univariate analyses.
p-Values< 0.05 were considered to be significant.
Results
A total of 137 ‘IPAH lung disease’ and 355 ‘IPAH no lung disease’
patients were included in this study. Five patients were lost
to follow up. The types of lung disease in patients with
‘IPAH lung disease’ were as follows: emphysema only
(n¼ 86), pulmonary fibrosis only (n¼ 34) and emphysema
and pulmonary fibrosis (n¼ 17). All ‘IPAH lung disease’
patients had FEV1 and FVC> 60% predicted.
Demographics, pulmonary function and haemodynamics
Baseline characteristics of ‘IPAH lung disease’ patients were
compared with ‘IPAH no lung disease’ patients diagnosed
over the same period in the UK and Ireland (Table 1).
Compared with ‘IPAH no lung disease’, ‘IPAH lung disease’
patients were older, had lower body mass index, were pre-
dominantly male and current or ex-smokers; 21% (n¼ 28)
of ‘IPAH lung disease’ patients had diabetes and 31% (n¼ 41)
had ischaemic heart disease, compared with 13% (n¼ 44,
p< 0.001) with diabetes and 12% (n¼ 42, p< 0.001) with
ischaemic heart disease in ‘IPAH no lung disease’. However,
left ventricular function was normal in all patients at Echo
and RHC. Despite similar functional class distribution,
‘IPAH lung disease’ patients had lower mean six-minute walk
distances (6MWDs) at the time of diagnosis compared with
‘IPAH no lung disease’. Mean values of spirometry and lung
volumes were within normal limits in both groups of
patients, whereas % predicted diffusion capacity for
carbon monoxide (%DLCO) was impaired in ‘IPAH lung dis-
ease’ patients. Mean pulmonary artery pressure (mPAP) and
pulmonary vascular resistance index were significantly lower
in ‘IPAH lung disease’ patients compared with ‘IPAH no lung
disease’ patients; 96% (n¼ 129) of patients with ‘IPAH lung
disease’ had severe PH (mPAP 35mmHg or
mPAP 25mmHg with cardiac index< 2.0 L.min–1.m–2) as
defined by Nice 2018 criteria.4
Treatment for ‘IPAH lung disease’ and ‘IPAH no lung disease’
All patients were treatment-naive at the time of diagnosis of
PH. First-line treatment data for ‘IPAH lung disease’ and
‘IPAH no lung disease’ patients are shown in Table 2; 27%
(n¼ 37) of ‘IPAH lung disease’ patients received combination
therapy over the study period compared with 47% (n¼ 167)
of ‘IPAH no lung disease’ patients (p< 0.001); 21% (n¼ 29) of
‘IPAH lung disease’ patients received prostanoids over the
study period compared with 39% (n¼ 139) of ‘IPAH no
lung disease’ patients (p< 0.001).
Paired 6MWD at baseline and three months were available
for 176 patients. 6MWD improved by 51 (95%CI: 22.6–78.7)
metres after three months of disease-targeted therapies in
‘IPAH lung disease’ patients compared with 46 (95% CI: 32.4–
59.9) metres in ‘IPAH no lung disease’ patients (p¼ 0.753).
Absolute 6MWD at three months was 258 ( 144.4) metres
in ‘IPAH lung disease’ patients compared with 347 ( 108.7)
metres in ‘IPAH no lung disease’ patients (p< 0.001).
Functional class at three months was available for 299
patients. After three months of PH-targeted treatment, 17%
(n¼ 14), 74% (n¼ 61) and 8.5% (n¼ 7) of ‘IPAH lung disease’
patients remained in functional class I/II, III and IV,
respectively. In ‘IPAH no lung disease’ patients, after three
months of PAH treatment, 32% (n¼ 69), 59.0% (n¼ 128)
and 9.2% (n¼ 20) remained in functional class I/II, III and
IV, respectively.
Survival
Eighty-nine ‘IPAH no lung disease’ and 61 ‘IPAH lung disease’
patients died over the study period. ‘IPAH lung disease’
patients had overall worse survival compared with ‘IPAH
no lung disease’ patients. One-, two- and three-year survival of
‘IPAH lung disease’ patients were 72%, 52% and 42%, respect-
ively. This is less compared with one-, two- and three-year
survival of 93%, 82% and 71%, respectively, in ‘IPAH no
lung disease’ patients (p< 0.001). Even after adjusting for age,
gender, smoking history, co-morbidities and haemo-
dynamics parameters, ‘IPAH lung disease’ patients were more
likely to have a shorter time to death or transplantation
compared with ‘IPAH no lung disease’ patients (Table 3).
Discussion
We report on the baseline characteristics and outcomes of
a subgroup of IPAH patients characterised by severe
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Table 1. Comparison of baseline demographics, pulmonary function tests and haemodynamics parameters between patients with ‘IPAH lung
disease’ and ‘IPAH no lung disease’.
Baseline characteristics
‘IPAH lung disease’
(n¼ 137)
‘IPAH no lung disease’
(n¼ 355) p-Values
Age, years (n¼ 492) 68 (11.2) 50 (17.1) <0.001
Gender, % female (n¼ 492) 41% (56) 71% (251) <0.001
Ethnicity, % non-white (n¼ 436) 0% (0) 11% (35) <0.001
Baseline functional class (n¼ 482)
I and II 10% (14) 15% (51) 0.469
III 70% (93) 67% (233)
IV 20% (27) 18% (64)
Smoking history (n¼ 404)
Current smoker 14% (17) 14% (39) <0.001
Ex-smoker 75% (91) 40% (114)
Never smoke 11% (13) 46% (130)
Baseline 6MWD, metres (n¼ 262) 210 (117.1) 292 (119.5) <0.001
Duration of symptoms, months, median (IQR) (n¼ 439) 18 (10.8–36.0) 18 (10.0–36.0) 0.880
Body mass index (n¼ 428) 26 (6.0) 29 (6.6) <0.001
% obesity (n¼ 428) 17% (21) 34% (105) <0.001
Haemoglobin, g/dL (n¼ 438) 15.3 (1.8) 15.1 (2.1) 0.347
% FEV1 (n¼ 399) 88 (18.1) 85 (14.3) 0.070
% FVC (n¼ 396) 103 (20.0) 94 (16.3) <0.001
FEV1/FVC ratio (n¼ 412) 68 (9.6) 75 (8.7) <0.001
% TLC (n¼ 232) 107 (99.5) 100 (64.1) 0.517
% DLCO (n¼ 374) 38 (20.1) 61 (21.0) <0.001
mRAP, mmHg (n¼ 467) 9.5 (5.2) 10 (5.8) 0.468
mPAP, mmHg (n¼ 479) 48 (9.0) 54 (14.1) <0.001
PCWP, mmHg (n¼ 445) 9.4 (3.3) 9.0 (3.7) 0.386
CI, L.min–1.m–2 (n¼ 404) 2.0 (0.6) 2.1 (0.7) 0.258
PVRI, WU.m–2 (n¼ 403) 21 (8.3) 23 (10.0) 0.019
6MWD: six-minute walk distance; CI: cardiac index; % DLCO: % predicted diffusion capacity for carbon monoxide; % FEV1: % predicted forced expiratory volume in
1 second; % FVC: % predicted forced vital capacity; IPAH; idiopathic pulmonary arterial hypertension; IQR: interquartile range; mPAP: mean pulmonary artery
pressure; mRAP: mean right atrial pressure; PCWP: pulmonary capillary wedge pressure; PVRI: pulmonary vascular resistance index; % TLC: % predicted total lung
capacity; WU: Woods unit.
Note: Results presented as mean SD or % (n) unless otherwise specified.
Table 2. Comparisons of treatment between ‘IPAH lung disease’ and ‘IPAH no lung disease’.
‘IPAH lung disease’
(n¼ 137)
‘IPAH no lung disease’
(n¼ 355) p-Values
Lung transplantation (n¼ 492) 0% (0) 2.5% (9) 0.068
Atrial septostomy (n¼ 492) 0% (0) 1.1% (4) 0.580
First-line treatment (n¼ 491)
No treatment 0.7% (1) 0.8% (3) <0.001
PD5i 53% (73) 30% (106)
ERA 32% (44) 44% (155)
Prostanoids 7.4% (10) 19% (66)
Calcium channel blockers 2.9% (4) 5.1% (18)
Combination therapy 2.9% (4) 2.0% (7)
ERA: endothelin receptor antagonist; IPAH: idiopathic pulmonary arterial hypertension; PD5i: phosphodiesterase type V inhibitor.
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pre-capillary PH, presence of minor co-existing lung disease
on thoracic CT (IPAH lung disease), absence of ventilatory
impairment on pulmonary function testing and normal
respiratory examination who were treated with PH-targeted
therapies. These patients were managed as IPAH no lung disease
patients in real life. They would not be excluded by pulmon-
ary function criteria in PAH clinical trials. Hence, many of
these patients were probably recruited as IPAH in pivotal
PAH clinical trials that form the evidence base for our cur-
rent practice. However, our results show that the phenotype
and response to treatment of these ‘IPAH lung disease’ patients
are different compared with ‘IPAH no lung disease’ patients.
The short-term improvement in 6MWD in response to PH
disease-targeted therapies in ‘IPAH lung disease’ patients may
have contributed to the positive results of PAH trials, many
of which used change in 6MWD as the primary endpoint.
However, functional class after three months of treatment
and survival of ‘IPAH lung disease’ patients appeared to be
significantly worse than ‘IPAH no lung disease’ patients and
long-term survival for ‘IPAH lung disease’ was worse than
‘IPAH no lung disease’ despite similar haemodynamics at
baseline.
‘IPAH lung disease’ patients described in our study had
normal clinical features, spirometry and lung volumes. The
most common parenchymal abnormality in our study
cohort was emphysema. Emphysema may be noted on CT
in otherwise asymptomatic healthy smokers and may not be
associated with airflow obstruction on spirometry.5
Interstitial changes are also frequently seen on the CT of
asymptomatic elderly patients and would not normally be
of any clinical relevance.5 It is possible that this selective
group of ‘IPAH lung disease’ patients described in our study
simply represents IPAH patients where the predominant dis-
ease is PAH and the parenchymal abnormality is an inci-
dental insignificant finding noted on thoracic CT done as
part of the standard assessment of PH. However, the differ-
ences in phenotypes and the worse survival of this group of
patients compared with ‘IPAH no lung disease’ suggest that
‘IPAH lung disease’ patients are indeed a separate subgroup
different to ‘IPAH no lung disease’ patients.
Alternatively, some may argue that ‘IPAH lung disease’
patients in our study are Group 3 PH patients with severe
PH. However, most COPD patients with severe PH also
have mild- to moderate airflow obstruction,6,7 whereas spir-
ometry was within normal limits in our ‘IPAH lung disease’
patients and fulfilled the inclusion criteria of PAH clinical
trials as Group 1 PH patients. Indeed, spirometry was better
in ‘IPAH lung disease’ than in ‘IPAH no lung disease’. A recent
case report of three patients also described a similar pheno-
type to our study cohort: elderly male smokers with normal
spirometry and lung volumes, emphysema on CT, severely
reduced DLCO and severe precapillary PH.
8 With our larger
patient number, our study not only confirmed the presence
of this separate PH phenotype but also allowed comparison
of this selective group of patients with ‘IPAH no lung disease’
patients diagnosed and managed concurrently at the same
PH centres.
Our study is multicentre and confirmed recent
results from the Scottish Pulmonary Vascular Unit
that showed different phenotype and poorer response to
treatment of lung disease patients with severe PH compared
with IPAH patients.9 In that study, 88 patients had
severe PH, of which 32 patients had mild lung disease and
the rest had severe lung disease.8 The ASPIRE registry
also reported on the characteristics and outcomes
of COPD patients with severe PH.11 In that study,
mean % FEV1 was 65% in COPD patients with
severe PH, whereas spirometry was normal in our
‘IPAHlung disease’ cohort.
The higher prevalence of smokers amongst the ‘IPAH lung
disease’ patients may explain the lower DLCO observed in
‘IPAH lung disease’ patients. Smoking is associated with sub-
clinical interstitial lung abnormalities,11,12 which in turn is
associated with lower DLCO and 6MWD.
13,14 Furthermore,
tobacco smoke may have a direct effect on the pulmonary
vasculature. Cigarette smoking has been associated with
smooth muscle cell proliferation and extracellular matrix-
protein deposition in pulmonary artery wall of smokers
who have not yet developed COPD.15 Cigarette smoking
was also associated with reduced expression of endothelial
nitric oxide synthase in pulmonary arteries of smokers with
airway disease.16
Table 3. Multivariate Cox regression models to determine whether
‘IPAH lung disease’ and ‘IPAH no lung disease’ patients differ after adjusting for
confounders.
p-Values
Hazard
ratio
95% confidence
interval
Model 1
Diagnosis
‘IPAH no lung disease’ 1
‘IPAH lung disease’ 0.01 1.71 1.108–2.631
Age, years <0.001 1.035 1.018–1.051
Male gender 0.94 1.02 0.688–1.498
Smoking history
Never smoker 1
Current/ex-smoker 0.04 1.56 1.023–2.445
Ischaemic heart disease 0.94 0.98 0.626–1.546
Hypertension 0.63 1.11 0.731–1.674
Diabetes 0.008 1.83 1.171–2.854
Model 2
Diagnosis
‘IPAH no lung disease’ 1
‘IPAH lung disease’ <0.001 2.72 1.863–3.980
mRAP, mmHg 0.60 1.01 0.973–1.049
SvO2, % 0.1 0.98 0.955–1.004
CI, L.min–1.m–2 0.02 0.64 0.440–0.938
CI: cardiac index; IPAH: idiopathic pulmonary arterial hypertension; mRAP:
mean right atrial pressure; SvO2: mixed venous oxygen saturations.
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The short-term improvement in 6MWD observed in
‘IPAH lung disease’ patients in our study cohort did not
appear to translate into similar improvement in functional
class or survival benefit to that observed in ‘IPAH no lung
disease’ patients. This is important because short-term
improvement in 6MWD has been used as primary end
point in many clinical trials of PH-targeted therapies. The
poor long-term prognosis of ‘IPAH lung disease’ patients may
be explained by the lower absolute 6MWD achieved by
‘IPAH lung disease’ patients at three months. Absolute
6MWD after three months of PAH treatment predicts
survival in IPAH, whereas change in 6MWD does not.17
PH-targeted therapies have vasodilatory and anti-prolifera-
tive properties and may help to unload the right ventricle to
account for the short-term improvement in exercise cap-
acity. However, other factors such as older age with asso-
ciated co-morbidities and the effect of smoking may
contribute to the worse survival of ‘IPAH lung disease’ patients
compared with ‘IPAH no lung disease’ patients in our study.
The male sex predominance amongst ‘IPAH lung disease’
patients may also account for the survival difference. Male
sex is associated with worse pulmonary haemodynamics,
reduced right ventricle response to treatment and worse
overall survival in PAH.18–20 In addition, a higher propor-
tion of ‘IPAH no lung disease’ patients received combination
therapy and prostanoids compared with ‘IPAH lung disease’
patients in our study.
With the exception of the presence of incidental par-
enchymal lung abnormalities on thoracic CT, ‘IPAH lung
disease’ patients described in this study otherwise satisfied
the haemodynamic and pulmonary function criteria of
IPAH and would have been – and, in many cases were
– classified as IPAH in real life or in clinical trials.
Disproportionately reduced DLCO as noted in our
‘IPAH lung disease’ cohort should raise the suspicion of
co-existing parenchymal lung disease even in the absence
of ventilatory impairment on pulmonary function testing.
Trip et al. similarly noted higher proportion of co-exist-
ing lung disease on thoracic CT in IPAH patients with
severely reduced DLCO.
3 ‘IPAH lung disease’ patients need
to be monitored closely because, despite similar short-
term improvement in 6MWD compared with ‘IPAH no
lung disease’ patients, the survival of ‘IPAH lung disease’
patients was relatively poor, and worse than ‘IPAH no
lung disease’ despite treatment with PH-targeted therapies.
On the face of it, our patients fit with the classification
of Pulmonary Vascular Phenotype in COPD.21 They have
severe precapillary PH and reduced DLCO but crucially
they do not have airflow limitation and would be (were)
recruited into clinical trials of patients with Group 1
PAH. More randomised controlled studies are needed
to inform whether the use of PH-targeted therapies is
beneficial in ‘IPAH lung disease’ patients. Better understand-
ing of the phenotype of this subgroup of IPAH patients,
as described in our study, may help to inform the selec-
tion of patients for future PAH trials. IPAH lung disease
patients should be recognised and recruited as a separate
subgroup to ‘IPAH no lung disease’ patients in future PAH
clinical trials.
Limitations of our study
Our study has several limitations. This was a retrospect-
ive observational study and we have not controlled for
treatment. It is possible that the presence of co-existing
subclinical radiographic lung disease may have biased the
choice of PH treatment and contributed to the worse
outcome of ‘IPAH lung disease’ patients. Missing 6MWD
data was unavoidable as not all centres used six-minute
walk test to assess exercise capacity. Some patients were
too unwell from their PH for their exercise capacity to
be assessed. The small number of non-white subjects in
our study may limit its generalisability. Our study popu-
lation was comprised of a heterogeneous group of
patients with different types and severity of parenchymal
lung disease, although in all cases, the abnormalities
were minor and associated with normal spirometry
allowing classification by PH experts as Group 1 PAH.
As CT images were not reviewed by an independent
reviewer, potential misclassification bias cannot be
excluded nor were the CT scans quantified. Chronic
alveolar hypoxia may trigger pulmonary vascular remo-
delling. Although data were not collected for hypoxia or
use of long-term oxygen therapy, there was no difference
in haemoglobin level between ‘IPAH no lung disease’ and
‘IPAH lung disease’. We do not have information on the
cause of death. That will be useful to confirm that the
increased risk of death of ‘IPAH lung disease’ patients is
not due to death unrelated to PH. Nevertheless, our
results showed increased risk of death of ‘IPAH lung dis-
ease’ patients after adjusting for age, gender, smoking
status and co-morbidities.
Conclusion
‘IPAH lung disease’ patients described in our study ful-
filled current inclusion criteria for clinical trials of
Group 1 PH patients and were treated as Group 1 PH
patients in real life. However, they had different phenotype
and outcomes compared with ‘IPAH no lung disease’ patients.
Thoracic CT and disproportionately reduced DLCO help to
differentiate ‘IPAH lung disease’ from ‘IPAH no lung disease’
patients. Despite similar baseline haemodynamic impair-
ment and similar short-term response to PH-targeted thera-
pies, survival of ‘IPAH lung disease’ was worse than ‘IPAH no
lung disease’. Age, the effect of smoking and the presence of
co-morbidities may account for the difference in long-
term outcome between these two subgroups of patients.
More emphasis should be put on differentiating between
subgroups of IPAH patients with or without co-existing
lung disease when designing future PH clinical trials.
Scoring the extent of parenchymal changes on thoracic
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CT should be employed in addition to standard
pulmonary function criteria when deciding whether a PH
patient should be Group 1, a variant of Group 1 or
Group 3 PH patient in future clinical trials and PH
registries.
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